相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
Sarah E. M. Herman et al.
BLOOD (2011)
Effect of PI3K-and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKBI-deficient mice
J. M. Garcia-Martinez et al.
BRITISH JOURNAL OF CANCER (2011)
Tumor Flare Reaction Associated With Lenalidomide Treatment in Patients With Chronic Lymphocytic Leukemia Predicts Clinical Response
Asher Chanan-Khan et al.
CANCER (2011)
PI3K/p110δ is a novel therapeutic target in multiple myeloma
Hiroshi Ikeda et al.
BLOOD (2010)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
Sverker Hasselblom et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Ben Markman et al.
ONCOTARGET (2010)
p110γ and p110δ isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease
Aurore Saudemont et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma
C. Renne et al.
LEUKEMIA (2007)
Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival
Shahab Uddin et al.
BLOOD (2006)
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Martina Rudelius et al.
BLOOD (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cutting edge:: Differential roles for phosphoinositide 3-kinases, p110γ and p110δ, in lymphocyte chemotaxis and homing
K Reif et al.
JOURNAL OF IMMUNOLOGY (2004)
分享论文
